Comparative Efficacy and Safety of Cilnidipine and Telmisartan in Hypertension: An 8 Week, Prospective Study
Authors/Creators
- 1. Assistant Professor, Dept. Of Pharmacology, Adesh Medical College & Hospital, Shahabad, Haryana
- 2. Professor & HOD, Dept. Of Pharmacology, Adesh Medical College & Hospital, Shahabad, Haryana
- 3. Professor, Dept. Of Pharmacology, Adesh Medical College & Hospital, Shahabad, Haryana
- 4. Professor, Dept. Of Medicine, Adesh Medical College & Hospital, Shahabad, Haryana
Description
Background: Hypertension is one of the most common disease affecting humans throughout the world. It is an important health issue due to the associated morbidity and mortality and the cost to society. Objectives: To evaluate and compare the efficacy and tolerability of Cilnidipine and Telmisartan in patients of stage I hypertension. Methods: This study included 50 patients with stage 1 hypertension. They were divided into two groups of 25 each to receive Cilnidipine and Telmisartan. Evaluation of efficacy was made by blood pressure measurement on day 0, week 2, week 4, week 6, and week 8. The difference in blood pressure reduction in two treatment groups from baseline to 8 weeks was the main outcome measure. Any adverse drug reactions were inquired, analyzed and recorded at each visit. Results: At 8 weeks, both groups showed significant (P<0.001) reduction in B.P from baseline. Mean SBP was reduced from 153.28 ± 4.5 mm Hg to 135.5 ± 5.0 mm Hg (Cilnidipine) and 154.04 ± 3.1 mm Hg to 136.56 ± 6.7 mm Hg (Telmisartan) after 8 weeks treatment (percentage difference was 11.5%, 11.9%). Mean DBP was reduced from 93.92 ± 4.3 mm Hg to 80.6 ± 1.9 mm Hg (Cilnidipine) and 94.48 ± 3.4 mm Hg to 81.2 ± 4.04 mm Hg (Telmisartan) after 8 weeks treatment (percentage difference was 14.18%, 14.05%). Conclusion: Both the drugs were equally efficacious in reducing blood pressure. The most common adverse effect reported was headache. All adverse effects were mild and did not require any alteration or discontinuation of treatment.
Abstract (English)
Background: Hypertension is one of the most common disease affecting humans throughout the world. It is an important health issue due to the associated morbidity and mortality and the cost to society. Objectives: To evaluate and compare the efficacy and tolerability of Cilnidipine and Telmisartan in patients of stage I hypertension. Methods: This study included 50 patients with stage 1 hypertension. They were divided into two groups of 25 each to receive Cilnidipine and Telmisartan. Evaluation of efficacy was made by blood pressure measurement on day 0, week 2, week 4, week 6, and week 8. The difference in blood pressure reduction in two treatment groups from baseline to 8 weeks was the main outcome measure. Any adverse drug reactions were inquired, analyzed and recorded at each visit. Results: At 8 weeks, both groups showed significant (P<0.001) reduction in B.P from baseline. Mean SBP was reduced from 153.28 ± 4.5 mm Hg to 135.5 ± 5.0 mm Hg (Cilnidipine) and 154.04 ± 3.1 mm Hg to 136.56 ± 6.7 mm Hg (Telmisartan) after 8 weeks treatment (percentage difference was 11.5%, 11.9%). Mean DBP was reduced from 93.92 ± 4.3 mm Hg to 80.6 ± 1.9 mm Hg (Cilnidipine) and 94.48 ± 3.4 mm Hg to 81.2 ± 4.04 mm Hg (Telmisartan) after 8 weeks treatment (percentage difference was 14.18%, 14.05%). Conclusion: Both the drugs were equally efficacious in reducing blood pressure. The most common adverse effect reported was headache. All adverse effects were mild and did not require any alteration or discontinuation of treatment.
Files
IJPCR,Vol16,Issue11,Article18.pdf
Files
(434.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:1311dcc1dc8cf0a773aa28d8421085d0
|
434.0 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-10-26
Software
- Repository URL
- http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue11,Article18.pdf
- Development Status
- Active
References
- 1. Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: The ICMR-INDIAB national crosssectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol 2023; 11:474-89. 2. Bhatia M, Kumar M, Dixit P, Dwivedi LK. Diagnosis and Treatment of Hypertension among people aged 45 years and over in India: A sub-national analysis of the variation in Performance of Indian states. Front Public Health 2021; 9:766458. 3. Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, Kirpalani A, et al. Indian guidelines on hypertension-IV (2019). J Hum Hypertens 2020;34(11):745-58. 4. Amarchand R, Kulothungan V, Krishnan A, Mathur P. Hypertension treatment cascade in India: Results from National Noncommunicable Disease Monitoring Survey. J Hum Hypertens 2023; 37:394-404. 5. Chandra SK, Ramesh G. The fourth-generation calcium channel blocker: Cilnidipine. Ind Heart J 2013; 65:691-5. 6. Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res.2006;29(11):839-47. 7. Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. CardiovascTher 2009;27(2):124-39. 8. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, Nitta K. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin- aldosterone system in SHR/ Izm. Am J Nephrol 2009;30(2):155-61. 9. Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18:127-56. 10. Kokiwar PR, Gupta SS. Prevalence of hypertension in a rural community of central India. Int Bio Med Res 2011;2(4):950-3. 11. Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009;27(2):124-39. 12. Kario K, Nariyama J, Kido H, Ando S, Takiuchi S, Eguchi K, Niijima Y, Ando T, Noda M. Effect of a novel calcium channel blocker on abnormal nocturnal blood pressure in hypertensive patients. J Clin Hypertens (Greenwich). 2013;15(7):465-72. 13. Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol 2010; 42(3): 153-6. 14. Xu G, Wu H, Du B, Qin L. The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients. Cardiovasc Hematol Disord Drug Targets2012;12(1):56-62.